A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs TSB 9-W1 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 09 Jan 2018 Planned number of patients changed from 30 to 12.
- 09 Jan 2018 Planned End Date changed from 1 Nov 2017 to 31 Dec 2018.
- 09 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 31 Dec 2018.